<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="original work is properly cited.http://www.gvt-journal.com/content/9/1/11 Abstract Hepatitis C virus (HCV)" exact="infection" post="is a major worldwide problem causes acute and chronic"/>
 <result pre="major worldwide problem causes acute and chronic HCV infection. Current" exact="treatment" post="of HCV includes pegylated interferon-α (PEG IFN- α) plus"/>
 <result pre="the nonstructural (NS) replicative proteins in the rest. (5) HCV" exact="infection" post="is generally going to be clinically imperceptible after 3-12"/>
 <result pre="estimated that 50-80% of patients have successively infected with chronic" exact="infection" post="and 2-5% have developed hepatocellular carcinoma per annum. HCV"/>
 <result pre="fibrogenetic effects [6] leading to steatosis and cirrhosis [7]. HCV" exact="infection" post="commences while interaction of virions instigate with various cellular"/>
 <result pre="regime for the deterrence of HCV infection. Nevertheless, current standard" exact="treatment" post="pegylated interferon-α (PEG IFN- α) in combination with ribavirin"/>
 <result pre="and polymerase inhibitors [13]. Various efforts are being made in" exact="screening" post="antiviral compounds against different HCV replicon systems [14-16]. Inhibitors"/>
 <result pre="encephylomyocarditis virus (EMCV)-HCV NS3-4A-4B-5A-5B-HCV 3' UTR. RNA replication, virus-host relations," exact="screening" post="of antiviral drugs and their mechanism are best studied"/>
 <result pre="may prove to be a striking antiviral agent for the" exact="treatment" post="of HCV infection [24]. In phase II study of"/>
 <result pre="be a striking antiviral agent for the treatment of HCV" exact="infection" post="[24]. In phase II study of clinical trials, it"/>
 <result pre="the backbone of forthcoming combination therapy with other compounds for" exact="treatment" post="and as save therapy for patients anchoraging resistance mutations"/>
 <result pre="replicon variants. Conclusively, substantial antiviral efficiency was assessed in combinational" exact="treatment" post="along with low emergence rate of viral variants with"/>
 <result pre="peptidyl prolyl isomerase activity of CyP at nanomolar concentrations by" exact="testing" post="in HCV replicon cell line. Further clinical trials of"/>
 <result pre="benzotriazole helicase inhibitors were recognized throughout the duration of random" exact="screening" post="study [58,59]. In particular, 4, 5, 6, 7- tetrabromobenzotriazole"/>
 <result pre="in combinational therapy which may prove to be a better" exact="treatment" post="option than standard therapy. Competing interests The authors declare"/>
 <result pre="of HCV infectionCurr Pharm Des2008141646165410.2174/13816120878474677018673187 RajaNSJanjuaNKEpidemiology of hepatitis C virus" exact="infection" post="in Pakistan. J Microbiol Immunol InfectJ Microbiol Immunol Infect2008414818327420"/>
 <result pre="fibrosis -- from bench to bedsideJ Hepatol200338Suppl 1S385312591185 PoynardTRatziuVMcHutchisonJMannsMGoodmanZZeuzemSYounossiZAlbrechtJEffect of" exact="treatment" post="with peginterferon or interferon alfa-2b and ribavirin on steatosis"/>
 <result pre="vesiclesJ Virol200680115711157810.1128/JVI.01717-0617005647 FeldJJHoofnagleJHMechanism of action of interferon and ribavirin in" exact="treatment" post="of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients with chronic"/>
 <result pre="of SCY-635 in adult patients with chronic hepatitis C virus" exact="infection" post="ShiSTHerlihyKJGrahamJPFuhrmanSADoanCPargeHHickeyMGaoJYuXChauFIn vitro resistance study of AG-021541, a novel nonnucleoside"/>
</results>
